Literature DB >> 14723255

Acute hematogenous osteomyelitis and septic arthritis in children.

Hui-Chin Kao1, Yhu-Chering Huang, Cheng-Hsun Chiu, Luan-Yin Chang, Zhon-Liau Lee, Pei-Wen Chung, Feng-Chen Kao, Tzou-Yien Lin.   

Abstract

This retrospective study analyzed the clinical, bacteriological, and radiological features of pediatric patients with acute hematogenous osteomyelitis and septic arthritis. Eighty-four patients with septic arthritis and 39 with acute hematogenous osteomyelitis were enrolled. Their age ranged from 13 days to 17 years. In patients with septic arthritis, the hip joint was the most often infected site. The tibia was the most often involved site in acute hematogenous osteomyelitis. A bacteriological diagnosis was established in 78 (63%) patients. Overall, methicillin-susceptible Staphylococcus aureus (36 cases) was the most common causative organism identified, followed by methicillin-resistant S. aureus (10 cases). The median duration of antibiotic therapy was 33 days. Serum bactericidal titers were obtained for 19 (15%) of the 123 patients. The median duration of hospitalization and antibiotic treatment was not significantly different between patients with and without serum bactericidal titer testing. More patients without serum bactericidal titer testing had symptom relapse which required re-admission for further treatment. In conclusion, the incidence of methicillin-resistant S. aureus as a cause of bone and joint infections has been increasing. Serum bactericidal titer is valuable for the management of patients receiving sequential therapy for acute hematogenous osteomyelitis and septic arthritis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14723255

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  10 in total

1.  Medium-term results after total clavicle resection in cases of osteitis: a consecutive case series of five patients.

Authors:  Ralf Oheim; Arndt Peter Schulz; Rita Schoop; Cornelius H Grimme; Justus Gille; Ulf-Joachim Gerlach
Journal:  Int Orthop       Date:  2011-09-01       Impact factor: 3.075

2.  [Acute haematogenous osteomyelitis in children : Diagnostic algorithm and treatment strategies].

Authors:  M Willegger; A Kolb; R Windhager; C Chiari
Journal:  Orthopade       Date:  2017-06       Impact factor: 1.087

3.  [Medium-term results of surgical treatment for osteitis of the clavicle].

Authors:  R Oheim; J Gille; C H Grimme; D Hadler; S Wallstabe; U J Gerlach
Journal:  Unfallchirurg       Date:  2011-07       Impact factor: 1.000

4.  Musculoskeletal infection imaging: past, present, and future.

Authors:  Santiago Restrepo; Daniel Vargas; Roy Riascos; Hugo Cuellar
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

Review 5.  [Pediatric osteomyelitis].

Authors:  A Jansson; V Jansson; A von Liebe
Journal:  Orthopade       Date:  2009-03       Impact factor: 1.087

6.  Childhood osteomyelitis: imaging characteristics.

Authors:  Joost van Schuppen; Martine M A C van Doorn; Rick R van Rijn
Journal:  Insights Imaging       Date:  2012-08-10

7.  A porcine model of acute, haematogenous, localized osteomyelitis due to Staphylococcus aureus: a pathomorphological study.

Authors:  Louise Kruse Johansen; Dorte Frees; Bent Aalbaek; Janne Koch; Tine Iburg; Ole Lerberg Nielsen; Pall Skuli Leifsson; Henrik Elvang Jensen
Journal:  APMIS       Date:  2010-12-01       Impact factor: 3.205

8.  Septic arthritis caused by kingella kingae: a case report.

Authors:  J Mardaneh; G Eslami; F Fallah; H Goudarzi; M M Soltan Dallal
Journal:  Iran Red Crescent Med J       Date:  2011-12-01       Impact factor: 0.611

9.  Septic Arthritis of the Pediatric Shoulder: From Infancy to Adolescence.

Authors:  Justin W Walker; William L Hennrikus
Journal:  Int J Pediatr       Date:  2016-08-21

10.  Acute hematogenous osteomyelitis in pediatric patients: epidemiology and risk factors of a poor outcome.

Authors:  Bogdan Popescu; Iulia Tevanov; Madalina Carp; Alexandru Ulici
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.